Epizyme, Inc.
PRMT5 inhibitors and uses thereof

Last updated:

Abstract:

Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof. Described herein are methods of treating cancer using one or more PRMT5 inhibitors, for example using one or more compounds of Formulae (1-5) or (A-F), pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions thereof.

Status:
Grant
Type:

Utility

Filling date:

4 Aug 2015

Issue date:

19 May 2020